Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000500

Type of data
NGS (Exome)
NGS (RNA-seq)
NGS (scRNA-seq)
NGS (ChIP-seq)
Methylation array
Access criteria
Controlled-access (Type I)
Total data volume
1.3 TB
File formats
  • BAM
  • bigWig
  • IDAT
  • CSV
Research
hum0315
Date published
2022-01-14
Date modified
2025-10-28
DDBJ Search
JGAD000500 (opens in a new tab)
JGA Study
JGAS000385 (opens in a new tab)

Analysis method

WES

Materials and participants
infants with KMT2A-rearranged acute lymphoblastic leukemia (ICD10: C91.0): 31 cases
leukemia cells and matched normal blood cells: total 62 samples
  • Health status
    Affected
  • Subject count
    31 (Individual)
  • Age group
    Infant
Disease
infants with KMT2A-rearranged acute lymphoblastic leukemia (C910)
Sample description
DNAs extracted from leukemia cells and normal blood cells of patients
  • Tissue
    Leukemia cell
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
WES
Target
N/A
Reagent kit
SureSelect Human All Exon V5 + lincRNA
Fragmentation
Ultrasonic fragmentation
Platform
Illumina HiSeq 2500
Read type
Paired-end
Read length
100 bp
Reference genome
GRCh37
Data use policy
NBDC data sharing policy (JGAP000001)

RNA-seq

Materials and participants
infants with KMT2A-rearranged acute lymphoblastic leukemia (ICD10: C91.0): 61 cases
cell lines derived from infants with KMT2A-rearranged acute lymphoblastic leukemia: 3 samples
  • Health status
    Affected
  • Subject count
    64 (Mixed)
  • Age group
    Infant
Disease
infants with KMT2A-rearranged acute lymphoblastic leukemia (C910)
Sample description
RNAs extracted from leukemia cells of patients and cell lines
  • Tissue
    Leukemia cell
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
RNA-seq
Target
N/A
Reagent kit
NEBNext Ultra RNA Library Prep Kit for Illumina
TruSeq RNA Library Prep Kit
Fragmentation
Enzymatic fragmentation
Platform
Illumina HiSeq 2500
Read type
Paired-end
Read length
100–150 bp
Reference genome
GRCh37
Data use policy
NBDC data sharing policy (JGAP000001)

scRNA-seq

Materials and participants
infants with KMT2A-rearranged acute lymphoblastic leukemia (ICD10: C91.0): 2 cases
  • Health status
    Affected
  • Subject count
    2 (Individual)
  • Age group
    Infant
Disease
infants with KMT2A-rearranged acute lymphoblastic leukemia (C910)
Sample description
RNAs extracted from leukemia cells of patients
  • Tissue
    Leukemia cell
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
scRNA-seq
Target
N/A
Reagent kit
BD Rhapsody WTA Amplification Kit
Fragmentation
N/A
Platform
Illumina HiSeq X
Read type
N/A
Read length
N/A
Data use policy
NBDC data sharing policy (JGAP000001)

ChIP-seq

Materials and participants
cell lines derived from infants with KMT2A-rearranged acute lymphoblastic leukemia: 3 samples
  • Health status
    Affected
  • Subject count
    3 (Sample)
  • Age group
    Infant
Sample description
DNAs extracted from cell lines, immunoprecipitated with an anti-histone antibody (H3K27Ac or H3K4me3) or anti-RNA Polymerase II antibody or anti-KMT2A antibody
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
ChIP-seq
Target
N/A
Reagent kit
TruSeq ChIP Sample Prep Kit
Fragmentation
Enzymatic fragmentation (MNase)
Platform
Illumina HiSeq 2500
Read type
Single-end
Read length
50 bp
Reference genome
GRCh37
Data use policy
NBDC data sharing policy (JGAP000001)

Targeted DNA sequencing

Materials and participants
infants with KMT2A-rearranged acute lymphoblastic leukemia (ICD10: C91.0): 72 cases
  • Health status
    Affected
  • Subject count
    72 (Individual)
  • Age group
    Infant
Disease
infants with KMT2A-rearranged acute lymphoblastic leukemia (C910)
Sample description
DNAs extracted from leukemia cells of patients
  • Tissue
    Leukemia cell
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
ARHGAP32, CDKN2A, CDKN2B, CHD4, CHD7, COL24A1, DDX10, DNHD1, FGF5, FLT3, IGSF9, JAG1, KRAS, MED12, NEB, NF1, NRAS, PAX5, PCDH19, PDGFRB, PICALM, PIK3CA, PIK3R1, PLXNA2, PTPN11, TP53, TTLL4, TUBGCP6, XBP1, XPO1
Reagent kit
SureSelect XT Low Input
Fragmentation
Ultrasonic fragmentation
Platform
Illumina HiSeq X
Read type
Paired-end
Read length
150 bp
Reference genome
GRCh37
Data use policy
NBDC data sharing policy (JGAP000001)

メチル化アレイ

Materials and participants
infants with KMT2A-rearranged acute lymphoblastic leukemia (ICD10: C91.0): 84 cases
EPIC: 25 cases
450K: 59 cases
  • Health status
    Affected
  • Subject count
    84 (Individual)
  • Age group
    Infant
Disease
infants with KMT2A-rearranged acute lymphoblastic leukemia (C910)
Sample description
DNAs extracted from leukemia cells of patients
  • Tissue
    Leukemia cell
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
Methylation array
Target
N/A
Reagent kit
Infinium HumanMethylation450 BeadChip Kit
Infinium MethylationEPIC BeadChip Kit
Platform
Illumina Infinium HumanMethylation450
Illumina Infinium MethylationEPIC
Probe count
EPIC: 866,836 probes
485,577 probes (450K)
Data use policy
NBDC data sharing policy (JGAP000001)